Four months after one of its scientists was snubbed for a Nobel Prize in medicine, a leading cancer center will ask a court to credit him in another way: by adding his name to patents underlying a major cancer immunotherapy drug made possible by the award-winning research.

Dana-Farber Cancer Institute on Monday will petition the U.S. District Court in Boston to include Gordon Freeman and a colleague on six patents issued by the U.S. Patent Office. Those patents currently name Nobel laureate Tasuku Honjo, two Kyoto University colleagues, and one scientist from the drug maker Ono Pharmaceutical.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy